Composite Endpoints In Fibromyalgia Subject Of Dueling Citizen Petitions
In trying to convince FDA to take Cypress Biosciences and Forest Laboratories' fibromyalgia drug Savella (milnacipran) off the market, the advocacy group Public Citizen has set itself the difficult task of arguing the agency out of its established policy of accepting clinical trials with composite endpoints as proof of efficacy against the disease.
You may also be interested in...
If Jazz's sodium oxybate is approved to treat fibromyalgia, it will go to market without a sleep claim to differentiate it from competitors
CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.
FDA missed the user fee goal date for Forest's Savella (milnacipran) due to an investigation of late-breaking whistleblower allegations, review documents for the fibromyalgia therapy show